These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 34622970)
61. Cutaneous presentation of ALK-positive anaplastic large cell lymphoma following insect bites: evidence for an association in five cases. Lamant L; Pileri S; Sabattini E; Brugières L; Jaffe ES; Delsol G Haematologica; 2010 Mar; 95(3):449-55. PubMed ID: 19951975 [TBL] [Abstract][Full Text] [Related]
62. Primary cutaneous anaplastic large-cell lymphoma resembling infratemporal space infection: a case report. Yan X; Ren W; Li S; Zhu Z; Gao L; Zhi K BMC Oral Health; 2024 Apr; 24(1):470. PubMed ID: 38637781 [TBL] [Abstract][Full Text] [Related]
63. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Feldman AL; Dogan A; Smith DI; Law ME; Ansell SM; Johnson SH; Porcher JC; Ozsan N; Wieben ED; Eckloff BW; Vasmatzis G Blood; 2011 Jan; 117(3):915-9. PubMed ID: 21030553 [TBL] [Abstract][Full Text] [Related]
64. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options. Querfeld C; Khan I; Mahon B; Nelson BP; Rosen ST; Evens AM Oncology (Williston Park); 2010 Jun; 24(7):574-87. PubMed ID: 20669794 [TBL] [Abstract][Full Text] [Related]
65. Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. Wang X; Boddicker RL; Dasari S; Sidhu JS; Kadin ME; Macon WR; Ansell SM; Ketterling RP; Rech KL; Feldman AL Hum Pathol; 2017 Jun; 64():19-27. PubMed ID: 28153507 [TBL] [Abstract][Full Text] [Related]
66. Cutaneous anaplastic large-cell lymphoma should be evaluated for systemic involvement regardless of ALK-1 status: case reports and review of literature. Yang S; Khera P; Wahlgren C; Ho J; Jukic D; Geskin L; English JC Am J Clin Dermatol; 2011 Jun; 12(3):203-9. PubMed ID: 21366363 [TBL] [Abstract][Full Text] [Related]
67. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin. Oregel KZ; Everett E; Zhang X; Nagaraj G Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026 [TBL] [Abstract][Full Text] [Related]
68. The clinicopathological relevance of uniform CD56 expression in anaplastic large cell lymphoma: a retrospective analysis of 18 cases. Yu BH; Zhang Y; Xue T; Shui RH; Lu HF; Zhou XY; Zhu XZ; Li XQ Diagn Pathol; 2021 Jan; 16(1):1. PubMed ID: 33402163 [TBL] [Abstract][Full Text] [Related]
69. Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative. Kadin ME; Pinkus JL; Pinkus GS; Duran IH; Fuller CE; Onciu M; Kawaguchi H; Morris SW Am J Surg Pathol; 2008 Sep; 32(9):1421-6. PubMed ID: 18670345 [TBL] [Abstract][Full Text] [Related]
70. Anaplastic Large Cell Lymphoma Manifesting as Pleural Effusion in a Patient with Long-Standing Eosinophilia. Belludi CK; Qian ET; Tolle JJ; Brown RM; Thompson MA; Juskevicius R Lab Med; 2019 Jan; 50(1):87-92. PubMed ID: 30016448 [TBL] [Abstract][Full Text] [Related]
71. Anaplastic large-cell lymphoma associated with acquired ichthyosis. Kato N; Yasukawa K; Kimura K; Yoshida K J Am Acad Dermatol; 2000 May; 42(5 Pt 2):914-20. PubMed ID: 10767704 [TBL] [Abstract][Full Text] [Related]